Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cognition Therapeutics ( (CGTX) ) has issued an update.
On March 26, 2026, Cognition Therapeutics reported fourth-quarter and full-year 2025 results and detailed progress in advancing its lead drug zervimesine for neurodegenerative indications. The company is prioritizing development of zervimesine for psychosis associated with dementia with Lewy bodies, following strong Phase 2 SHIMMER data, and plans a mid-2026 meeting with the FDA’s Division of Psychiatry to align on a registrational pathway while also offering an expanded access program for DLB patients.
In Alzheimer’s disease, Cognition completed enrollment in December 2025 in the 545-patient Phase 2 START trial in mild cognitive impairment and early Alzheimer’s, with topline data expected in 2027 to guide decisions on a potential registrational program. Financially, the company ended 2025 with $37.0 million in cash and $35.7 million in remaining NIH grant funding, reduced its annual net loss to $23.5 million from $34.0 million in 2024, and estimates its current resources will fund operations and capital expenditures through the second quarter of 2027, extending its runway as it moves zervimesine toward later-stage trials.
The most recent analyst rating on (CGTX) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Cognition Therapeutics stock, see the CGTX Stock Forecast page.
Spark’s Take on CGTX Stock
According to Spark, TipRanks’ AI Analyst, CGTX is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, large losses, and significant cash burn) and a soft technical setup (below key moving averages with negative MACD). A low-debt balance sheet and a positive FDA interaction supporting progression toward a Phase 2b trial provide partial offsets, but not enough to materially lift the overall risk profile.
To see Spark’s full report on CGTX stock, click here.
More about Cognition Therapeutics
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, accessible therapies for neurodegenerative diseases, including dementia with Lewy bodies (DLB), Alzheimer’s disease, geographic atrophy and Parkinson’s. Its lead candidate, zervimesine (CT1812), an investigational once-daily oral therapy targeting toxic oligomers, has shown promise in Phase 2 trials in DLB and mild-to-moderate Alzheimer’s disease and is supported by nearly $200 million in NIH and foundation grants.
The company’s scientific approach builds on established biological pathways implicated in degenerative nerve disorders and is designed to translate across multiple indications where toxic oligomers drive disease progression. This positions Cognition Therapeutics to address large, underserved patient populations and to potentially ease caregiver burden through disease-modifying treatments that can be delivered orally and integrated into routine care, if successfully developed and approved.
Average Trading Volume: 815,303
Technical Sentiment Signal: Sell
Current Market Cap: $97.98M
Find detailed analytics on CGTX stock on TipRanks’ Stock Analysis page.